Currently, 30 potential NASH drugs are in clinical studies in China, another eight candidates have submitted IND applications while six have already been greenlighted.
On November 14, FibroGen filed a federal lawsuit in California alleging that two of its former employees stole its anemia treatment work and established company in China to develop me-too drugs and apply for patents.
Nearly 20 products have undergone IPF clinical research in China. Roche's RG6354, FibroGen’s pamrevlumab, and Boehringer Ingelheim’s BI 1015550 have entered phase III clinical trials.
Chunlin Xin, Vice President of External Collaboration at CanSino Biologics, told PharmaDJ that “using the adenovirus type 5 vector may be the reason why we succeeded with making the world first inhaled COVID-19 vaccine.”
In September, the China National Intellectual Property Administration (CNIPA) once again ruled against HEC group in a recent patent infringement case with Boehringer Ingelheim over Boehringer’s self-developed drug Trajenta (linagliptin). The ruling has further affirmed Boehringer’s patent rights.
Since early 2022, biopharma stocks on the Hong Kong Exchange (HKEX) have experienced a sharp tumble. We interviewed three seasoned investors who nevertheless remain optimistic about the industry’s prospects.
Aleksandar Skuban, Brii Bio’s Head of Central Nervous System (CNS) Disease Therapy Area, believes that BRII-296 has potential to provide a more appealing, convenient and less stigama treatment option for postpartum depression (PPD) patients.
Lower IPO requirements and a hospitable stock exchange are making Singapore a new hotspot for Chinese biotechs looking to go public.
Immunotherapy specialist iCamuno is looking to make big strides in cancer treatment with its three groundbreaking new platforms and a clinical-grade cell bank.